SciELO - Scientific Electronic Library Online

 
 issue29Medication-related osteonecrosis of the jaw: current theoretical and useful concepts for the general practitioner author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Odontología Vital

On-line version ISSN 1659-0775Print version ISSN 1659-0775

Abstract

RIVERA PEREZ, José Manuel. Metabolic relationships of bisphosphonateinduced osteonecrosis of the jaw: review. Odontología Vital [online]. 2018, n.29, pp.7-18. ISSN 1659-0775.

Bifosphonates are antiresorptive drugs of choice in the treatment of a wide range of osteolytic pathologies, such as osteoporosis, Piaget’s disease, hypercalcemia associated with bone metastasis and bone lesions due to multiple myeloma, among others (Adober et ál., 2000). The orally use of these drugs reports adverse effects in the digestive tract: nausea, abdominal pain, heartburn, ulcers and esophageal stenosis (Jódar et ál., 2002). Since 2003, they have also been associated with a bone exposure in the maxilla called bisphosphonate-induced osteonecrosis of jaws; particularly in intravenous application with greater bioavailability (Marx et ál., 2003).

In patients who consume BFs aggressive dental treatments can trigger osteonecrosis of the jaw (Barquero, 2016).

The present review focuses on mechanisms of action of BFs that justify their therapeutic action and adverse effects, among them the development of osteonecrosis of jaw; also seeks to It also aims to draw attention to the need to establish dental protocols for patients who are treated with BFs for long periods.

Keywords : Bisphosphonates; osteonecrosis of the jaw; antiresorptive; antiangiogenic.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )